Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.

@article{Geller2015SystemicNA,
  title={Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.},
  author={Bram J. Geller and Robert P Giugliano and Eugene Braunwald and Sabina A. Murphy and James J. Hanyok and Jianqing Jin and Michele F. Mercuri and Elliott Marshall Antman and Christian Thomas Ruff},
  journal={American heart journal},
  year={2015},
  volume={170 4},
  pages={669-74}
}
BACKGROUND Atrial fibrillation (AF) is a major risk factor for stroke and systemic embolism. Trials comparing warfarin with non-vitamin K oral anticoagulants (NOACs) have demonstrated that, when compared with warfarin, the NOACs are at least as effective in preventing stroke, although detailed analyses characterizing systemic embolic events (SEEs) are lacking. METHODS AND RESULTS We performed a prespecified analysis in 21,105 patients with AF enrolled in the ENGAGE AF-TIMI 48 trial, which… CONTINUE READING

Similar Papers

Loading similar papers…